Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1702 - Randomized phase II trial of CAPOX with planned oxaliplatin stop-and-go strategy as adjuvant chemotherapy after curative resection of colon cancer (CCOG-1302 study)


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Hiroyuki Yokoyama


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


H. Yokoyama1, G. Nakayama2, K. Ishigure3, N. Hayashi4, K. Tanaka5, M. Tsutsuyama2, N. Hattori2, S. Yamada2, Y. Kodera2

Author affiliations

  • 1 Gastroenterological Surgery, Komaki City Hospital, 4858520 - Komaki/JP
  • 2 Gastroenterological Surgery, Nagoya University, Graduate School of Medicine, 466-8550 - Nagoya/JP
  • 3 Department Of Surgery, Konan Kosei Hospital, 4838704 - Konan/JP
  • 4 Surgery, Tosei General Hospital, 489-0065 - Seto/JP
  • 5 Surgery, Yokkaichi Municipal Hospital, 5108567 - Yokkaichi/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1702


The aim of this study was to evaluate the efficacy and safety of CAPOX with planned oxaliplatin stop-and-go strategy compared to continuous use of oxaliplatin as an adjuvant setting for colon cancer.


Patients with curative resection of colon cancerwere randomly assigned to receive eitherCAPOX with continuous use of oxaliplatin (8 cycles of CAPOX; continuous arm) or CAPOX intermittentuse of oxaliplatin (2 cycles of CAPOX – 4 cycles of capecitabine – 2 cycles of CAPOX; intermittentarm).The primary endpoints were frequency of peripheral sensory neuropathy (PSN) at 1-year after surgery and disease-free survival rate at 3-year after surgery. The secondary end points included overall survival (OS), compliance and safety.


A total of 200 patients were enrolled. The intent-to-treat and safety population comprised 100 and 99 patients in the continuous arm,and 100 and 98 patients in the intermittentarm. Compliance: The overall treatment completion rate and relative dose intensity of oxaliplatin were 64% and 71% in the continuous arm vs.92% and 95% in the intermittentarm(p = 0.21 and 0.12, respectively). Efficacy: The 3-year DFS was 81.6% in the continuous arm vs.82.4% in the intermittentarm(HR, 0.82; 95% CI, 0.48-1.18). Safety: The incidence of PSN (>grade 2) was 33%in the continuous arm vs.15% in the intermittentarm (p < 0.001). The frequencies ofPSF lasting for 1-year and 3-year were 61% and 30% vs. 21% and 6%, respectively.


CAPOX withplanned oxaliplatin stop-and-go strategy could be equally effectiveas an adjuvant setting for colon cancer, and substantially reduce long-term PSN and potential improve patient quality of life.

Clinical trial identification

000012535 (09/December/2013).

Editorial acknowledgement

Legal entity responsible for the study

Yasuhiro Kodera (Chubu Clinical Oncology Group, Japan).


Chubu Clinical Oncology Group.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.